Nisa Investment Advisors
ALNY icon

Nisa Investment Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Nisa Investment Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.75M Sell
9,139
-218
-2% -$65.8K 0.01% 553
2026
Q1 		$3.1M Sell
9,357
-292
-3% -$99.4K 0.01% 496
2025
Q4 		$3.84M Sell
9,649
-2,484
-20% -$1.1M 0.01% 474
2025
Q3 		$5.53M Buy
12,133
+3,891
+47% +$1.58M 0.02% 387
2025
Q2 		$2.69M Buy
8,242
+87
+1% +$24.1K 0.01% 558
2025
Q1 		$2.2M Sell
8,155
-5,162
-39% -$1.33M 0.01% 616
2024
Q4 		$3.13M Buy
13,317
+1,789
+16% +$470K 0.01% 557
2024
Q3 		$3.17M Buy
11,528
+3,373
+41% +$878K 0.02% 532
2024
Q2 		$1.98M Hold
8,155
– – 0.01% 699
2024
Q1 		$1.22M Hold
8,155
– – 0.01% 817
2023
Q4 		$1.56M Hold
8,155
– – 0.01% 729
2023
Q3 		$1.44M Hold
8,155
– – 0.01% 760
2023
Q2 		$1.55M Sell
8,155
-2,200
-21% -$436K 0.01% 745
2023
Q1 		$2.07M Sell
10,355
-25
-0.2% -$5.25K 0.02% 659
2022
Q4 		$2.47M Hold
10,380
– – 0.02% 671
2022
Q3 		$2.08M Sell
10,380
-353
-3% -$67.3K 0.02% 619
2022
Q2 		$1.56M Buy
10,733
+2,950
+38% +$419K 0.01% 699
2022
Q1 		$1.27M Sell
7,783
-984
-11% -$150K 0.01% 790
2021
Q4 		$1.21M Sell
8,767
-21,760
-71% -$4.04M 0.01% 782
2021
Q3 		$5.76M Buy
30,527
+17,415
+133% +$3.27M 0.04% 407
2021
Q2 		$2.22M Sell
13,112
-17,900
-58% -$2.62M 0.01% 689
2021
Q1 		$4.38M Buy
31,012
+15,700
+103% +$2.36M 0.03% 487
2020
Q4 		$1.99M Buy
15,312
+2,870
+23% +$383K 0.01% 696
2020
Q3 		$1.81M Sell
12,442
-4,416
-26% -$628K 0.01% 627
2020
Q2 		$2.5M Buy
16,858
+4,378
+35% +$590K 0.02% 528
2020
Q1 		$1.36M Buy
12,480
+2,000
+19% +$231K 0.02% 625
2019
Q4 		$1.21M Sell
10,480
-30,000
-74% -$2.99M 0.01% 821
2019
Q3 		$3.25M Buy
40,480
+33,132
+451% +$2.62M 0.03% 487
2019
Q2 		$533K Sell
7,348
-4,335
-37% -$333K 0.01% 1054
2019
Q1 		$1.09M Buy
11,683
+2,259
+24% +$189K 0.01% 819
2018
Q4 		$687K Sell
9,424
-400
-4% -$30.8K 0.01% 903
2018
Q3 		$860K Buy
9,824
+2,174
+28% +$219K 0.01% 936
2018
Q2 		$753K Buy
7,650
+6,150
+410% +$610K 0.01% 937
2018
Q1 		$179K Sell
1,500
-5,700
-79% -$735K ﹤0.01% 1263
2017
Q4 		$915K Buy
7,200
+700
+11% +$88K 0.01% 861
2017
Q3 		$764K Hold
6,500
– – 0.01% 909
2017
Q2 		$447K Buy
6,500
+1,500
+30% +$95.9K 0.01% 1054
2017
Q1 		$256K Buy
+5,000
New +$231K ﹤0.01% 1193
2016
Q4 		– Sell
-2,300
Closed -$156K – 1875
2016
Q3 		$156K Hold
2,300
– – ﹤0.01% 1269
2016
Q2 		$128K Buy
+2,300
New +$145K ﹤0.01% 1292

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nisa Investment Advisors's ALNY Position: Q2 2026 in Review

Nisa Investment Advisors reduced its Alnylam Pharmaceuticals (ALNY) stake by 2.3% in Q2 2026, selling an estimated $65.8K and leaving 9,139 shares worth $2.75M. The position accounts for 0.01% of the portfolio, ranked #553.

Nisa Investment Advisors first reported a position in ALNY in Q2 2016 and has held it in 40 quarters since. The position peaked at $5.76M in Q3 2021. 791 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Nisa Investment Advisors held 9,139 shares of Alnylam Pharmaceuticals worth $2.75M as of Q2 2026.
  • Nisa Investment Advisors sold 218 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $65.8K.
  • Alnylam Pharmaceuticals made up 0.01% of Nisa Investment Advisors's portfolio in Q2 2026, its #553 holding.
  • Nisa Investment Advisors first reported a position in Alnylam Pharmaceuticals in Q2 2016 and has held it in 40 quarters since.
  • Nisa Investment Advisors's Alnylam Pharmaceuticals position peaked at $5.76M in Q3 2021.
  • 791 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Nisa Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.